The journey of fighting Acute Myeloid Leukemia (AML) in India encompasses severe physical and emotional challenges for both ...

Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune ...

Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid ...

The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs ...

In the latest move to cement its “immunology powerhouse” status, Sanofi is handing ove | The CD20-directed antibody, dubbed ...

Sanofi to acquire Dren Bio's bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune syste ...

Sanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.

French pharma major Sanofi (Euronext: SAN) today revealed it has entered into a definitive agreement with privately-held US biotech Dren Bio, to acquire the latter’s DR-0201, a targeted bispecific ...

The following is a summary of “Improved survival in older patients with myeloid malignancies undergoing haploidentical ...

Sanofi has announced that it will be broadening its immunology pipeline by acquiring Dren Bio’s phase 1 CD20-directed bispecific myeloid cell engager for $600m upfront. Pre-clinical and early clinical ...

The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who ...

Paris: Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive ...